Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesClinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs
Journal of Clinical Endocrinology and Metabolism, 06/17/09
Noh JY et al. – Study reports that the time of onset of MPO-ANCA-associated vasculitis and the dose at onset varied. The severity and number of organs involved were not correlated with the MPO-ANCA titre, warranting the need for vigilance even when the titre is weakly positive.
Methods- An analysis of pts with MPO-ANCA-associated vasculitis to determine:
- Time of onset
- Drug and dose taken
- Clinical symptoms
- Relationship between the clinical symptoms and the MPO-ANCA titre, and the incidence
- 92 pts in whom the adverse reaction of MPO-ANCA-associated vasculitis was reported were analysed
- Organ failure reported as:
- 41/92 (44.6%) pts had single-organ failure
- 34.8% had two-organ failure
- 14.1% had three-organ failure
- 2.2% had four-organ failure
- Number of organs involved was unknown in 4.3% of pts
- Median time of onset was 42 mo after starting drug treatment
- Median dose at onset of MPO-ANCA-associated vasculitis was 15 mg/d for methimazole, and 200 mg/d for propylthiouracil
- Severity and number of organs involved were not correlated with the MPO-ANCA titre
- Incidence was between 0.53 and 0.79 pts per 10,000
- Ratio of the estimated incidences for methimazole and propylthiouracil was 1:39.2
Related Articles
European League Against Rheumatism/European Vasculitis Study Group recommendations for the management of vasculitis
Current Opinion in Rheumatology, 10/16/09
Relevance Score: 92%
Resolution of anti-neutrophil cytoplasmic antibody-associated vasculitis after resection of gastric cancer
Modern Rheumatology, 10/19/09
Relevance Score: 91%
Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9
Journal of Rheumatology, 10/20/09
Relevance Score: 89%
Cutaneous vasculitis induced by TNF inhibitors: a report of three cases
Modern Rheumatology, 10/16/09
Relevance Score: 88%
Analysis of T-cell receptor usage in myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis
Clinical and Experimental Nephrology, 10/09/09
Relevance Score: 88%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
TNF{alpha} blockade therapy reduces circulating NT-proBNP levels in RA patients with active disease: Results from prospective cohort study
Annals of Rheumatic Diseases, 12/07/09
Today in Vasculitic Syndromes...keeping you current
Receive free subspecialty "5-minute updates" via email
Invasive pulmonary aspergillosis in patients with antineutrophil cytoplasmic antibody associated vasculitis
Journal of Clinical Rheumatology (JCR), 12/07/09
Is there any relationship between serum and urine neopterin and serum interferon-gamma levels in the activity of Behcet's disease?
Journal of the European Academy of Dermatology and Venereology, 12/04/09
Rituximab may form a complex with iGm[kappa] mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis
Arthritis & Rheumatism, 12/03/09
Sponsor
Article Search
Sponsor